EGFR and non-small cell lung carcinoma: As for patients with nonsquamous NSCLC who were not positive for EGFR 19/21 mutation and received first‐line treatment, the ORR was 53.4% in patients who received ICI‐combined chemotherapy, and 40.2% in patients receiving ICI monotherapy (p = 0.027).